Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with coronary artery disease in Iran by Salimi, S. et al.
Original article 487Endothelial nitric oxide synthase gene intron4 VNTR
polymorphism in patients with chronic kidney disease
Manal F. Elshamaaa, Samar Sabryb, Ahmed Badrb, Mostafa El-Ahmadya,
Eman A. Elghorouryc, Eman H. Thabetc, Dina Kandilc and Solaf KamelcNitric oxide production is reduced in renal disease, partially
due to decreased endothelial nitric oxide production.
Evidence indicates that nitric oxide deficiency contributes to
cardiovascular events and progression of kidney damage. A
polymorphism in intron 4 of the endothelial constitutive
nitric oxide synthase (ecNOS) gene is a candidate gene in
cardiovascular and renal diseases. We investigated a
potential involvement of this polymorphism in chronic renal
failure. A case–control study involved 78 children with
chronic kidney disease (CKD) and 30 healthy controls. All
participants were genotyped for the ecNOS4 polymorphism
by the polymerase chain reaction (PCR). Dialyzed
(maintenance hemodialysis) and conservative treatment
children had significantly higher frequency of the aa
genotype and ecNOS4a allele (P<0.05) compared with
controls. The combined genotype aaRab vs. bb
comparison validated that a allele is a high-risk allele for
end-stage renal disease (ESRD) (P<0.05). Serum nitric
oxide level was found to be lower in carriers of the ecNOS
4a allele than in noncarriers (100.29W27.32 vs.
152.73W60.39mmol/l, PU0.04). Interestingly, 85.95% of
the ecNOS 4a allele ESRD patients were found hypertensive
in comparison to the 60.67% patients of non noncarriers (bb
genotype) (PU0.04). Also, 35.90% of the ecNOS 4a alleleCopyright © Lippincott Williams & Wilkins. Unaut
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in comparison to the 5.13% patients of noncarriers
(bb genotype) (PU0.01). On multiple linear regression
analysis, a allele was independently associated with
hypertension (PU0.03). There was a significantly higher
frequency of the ecNOS4a allele carriers among CKD
children, both on MHD and conservative treatment than in
controls. This suggests that the ecNOS gene polymorphism
may be associated with an increased risk of chronic renal
failure. Blood Coagul Fibrinolysis 22:487–492  2011
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Endothelial function is closely associated with blood
pressure and hypertension, and several studies found
endothelial dysfunction in normotensive siblings of
hypertensive individuals. Endothelial nitric oxide
synthase (eNOS), an enzyme that generates nitric oxide,
is a major determinant of endothelial function, suggesting
that polymorphisms in the eNOS gene may influence
the likelihood of blood pressure progression or incident
hypertension in an individual person. Nitric oxide is a
potent regulator of intrarenal hemodynamics [1]. At the
release site it mediates local vasodilatation, antagonizes
platelet aggregation and inhibits vascular smooth muscle
cell proliferation [2]. In the kidney, nitric oxide dilates
renal blood vessels and modulates renin secretion [3]. An
impairment of nitric oxide production causes abnormal-
ities in vascular function in many diseases including
human hypertension and renal disease [4,5].
The endothelial constitutive nitric oxide synthase
(ecNOS), which produces nitric oxide from L-arginine,
is encoded by a gene located on chromosome 7q35-36,
expressed in endothelium [6]. There are two alleles
identified in intron 4 of the ecNOS gene. The largerallele, 4b, consists of five tandem 27-bp repeats and the
smaller one, 4a, has four repeats [7]. An association of the
4a allele of the ecNOS gene with coronary heart disease
and renal disease was reported [4,8,9].
Chronic renal failure is basically a vascular disorder and
investigating ecNOS gene polymorphism might shed
some light on the pathophysiology of renal disease and
progression to end-stage renal disease (ESRD).
The study investigated: the relevance of the ecNOS intron
4 polymorphism to the development and progression of
chronic renal failure; its relationshipwithhypertension and
cardiovascular complications in chronic kidney disease
(CKD) pediatric patients undergoing maintenance hemo-
dialysis (MHD) or conservative treatment.
Patients and methods
Seventy-eight pediatric patients with advanced CKD
[stages 4 and 5 based on estimated glomerular filtration
rate (eGFR) according to the National Kidney Founda-
tion classification] [10] were included in the study. They
were divided into two groups undergoing conservative
treatment (n¼ 32) or MHD (n¼ 46). MHD children werehorized reproduction of this article is prohibited.
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Fig. 1
Genotyping of NOS polymorphism photographed on a 2% agarose gel
electrophoresis resolving the wild-type allele B at 420 bp and the
polymorphic allele A at 393 bp. Lanes (2, 3, 5, and 7) show a single
band at 420 bp representing the homozygous allele B pattern (NOSB/
B). Lanes (4 and 8) represent the heterozygous pattern for allele A and
allele B (NOSA/B). Lane (6) shows one band at 393 bp representing
the homozygous allele A pattern (NOSA/A). Lane (1) denotes molecular
weight ladder marker 100–1000 bp (Sigma, St. Louis, USA).selected from the hemodialysis unit of the Center of
Pediatric Nephrology and Transplantation (CPNT),
whereas children undergoing conservative treatment
were selected from the Nephrology pediatric clinic, Chil-
dren’s Hospital, Cairo University. The study was done
from April 2009 to December 2009. In conservative
treatment patients the causes of renal failure were renal
hypoplasia or dysplasia (n¼ 14), obstructive uropathies
(n¼ 8), neurogenic bladder (n¼ 4), not known (n¼ 4), or
metabolic (n¼ 2). In MHD, the causes of renal failure
were hereditary nephropathies (n¼ 17), obstructive uro-
pathies (n¼ 6), neurogenic bladder (n¼ 2), glomerulo-
pathy (n¼ 2), renal hypoplasia or dysplasia (n¼ 2), and
unknown causes (n¼ 17). The inclusion criteria forMHD
patients included patients with onset of hemodialysis
below 16 years with at least 6 months duration on
MHD. They were treated with hemodialysis for 3–4 h
three times weekly with a polysulfone membrane using
bicarbonate-buffered dialysate. The duration of hemo-
dialysis was 2.75 1.59 years. Thirty-two MHD patients
and 16 conservative treatment patients were taking
antihypertensive treatment.
All control children (n¼ 30) were healthy with no clinical
signs of vascular or renal disease and no family history of
renal disease. An informed consent for genetic studies
was obtained from parents of all participants. The pro-
tocol of the study was read and approved by the Ethics
Committee of NRC in Egypt.
Diagnostic criteria of vascular disease
We studied the prevalence of vascular disease in children
with CKD according to the following criteria [11].
Cardiac disease: the presence of primary dilated cardio-
myopathy previously diagnosed clinically and by echo-
cardiography.
Cerebral vascular disease: Cerebral vascular disease was
suspected on clinical grounds, that is, rapidly developing
signs of focal disturbance of cerebral function such as
hemiparesis and hemisensory impairment. The diagnosis
was confirmed by computed tomography or magnetic
resonance imaging. Brain hemorrhage and subarachnoid
hemorrhage were excluded.
Apatientwas considered tohave a vascular diseasewhen at
least oneof these twodefinedvascular diseasewas present.
Three millilitres of venous blood sample was collected in
EDTA vials for the extraction of genomic DNA. The
following parameters were measured: creatinine, urea,
electrolytes, total cholesterol, HDL cholesterol and tri-
glyceride by routine methods.
Quantitative determination of nitric oxide concentration
in serum
It is done by using the Griss reaction after ultrafiltration
via the immunosorbent assay (R&D system Inc., Min-
neapolis, Minnesota, USA) [12].opyright © Lippincott Williams & Wilkins. UnauthDetermination of ecNOS genotype
DNA was extracted from peripheral blood using a
QIAamp Blood miniprep extraction Kit (QIAGEN,
Germany) and was stored at 48C until analysis. eNOS
genotypes were determined by the polymerase chain
reaction (PCR). Briefly, the oligonucleotide primers
(the forward primer sequence was 50-AGGCCCTATGG
TAGTGCCTTT -30 which was located at position
5111–5130 base pairs of the genomic sequence of
NOS, and the sequence of the reverse primer was 50-
TCTCTTAGTGCTGTGGTCAC-30 which its position
within the genomic sequence of NOS was 5530–5511 bp)
that flank the region of the 27-bp direct repeat in eNOS
intron 4 were used for DNA amplification [13]. Each
reaction mixture was heated to 948C for 4min for dena-
turation and underwent 35 cycles at 948C for 1min,
annealing at 568C for 1min with an extension at 728C
for 2min, and a final extension at 748C for 7min. The
PCR products were analyzed by 2% agarose gel electro-
phoresis and fragments were visualized by ethidium
bromide staining and ultraviolet transillumination
(Fig. 1).
Statistical analysis
Statistical package for social science (SPSS, Chicago,
Illinois, USA) program version 11.0 was used for analysis
of data. Data were summarized as meanSD, range or
percentage. Data were evaluated between the experi-
mental groups by one-way analysis of variance (ANOVA).
Allele and genotypic frequencies for ecNOS alleles were
calculated with the gene counting method. Comparison
of the categorical data, that is different ecNOS genotypes
among patients was done by independent-samples t-test
when appropriate. Multiple regression analysis wasorized reproduction of this article is prohibited.
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Table 2 Frequencies of ecNOS intron 4 genotypes in patients and
controls
Gene CT (n¼32) MHD (n¼46) Controls (n¼30)
Alleles
b 43 (67.19%) 61 (66.30%) 47 (78.33%)
a 21 (32.81%) 31 (33.70%)b 13 (22.67%)
Genotypes
bb 16 (50%) 23 (50.00%) 17 (56.67%)
ab 11 (34.38%) 15 (32.61%) 13 (43.33%)
aa 5 (15.62%)a 8 (17.39%)b 0 (0.00%)
Data were evaluated by the gene counting method. Values are presented as
percentage. CT, conservative treatment; MHD, maintenance hemodialysis.
aP<0.05 vs. control and CT. bP<0.05 vs. control and MHD.performed to assess the influence of ecNOS alleles on
hypertension and vascular diseases. A P value of less than
0.05 was considered significant.
Results
Clinical and biochemical characteristics of the studied
groups were summarized in Table 1.
There were no significant differences between groups
with respect to age, sex ratio and total serum cholesterol
level. Serum nitric oxide level was significantly higher in
the both MHD and conservative treatment groups than
the controls and the level was significantly higher in
MHD group than conservative treatment group
(143.93 35.99, 91.48 28.80, and 51.84 12.39mmol/l,
respectively).
The distribution of genotypes and allele frequencies was
compared between patients and controls (Table 2). The
genotype frequencies were in agreement with Hardy–
Weinberg equilibrium. Dialyzed and conservative treat-
ment patients had significantly higher frequency of the aa
genotype and ecNOS4a allele (P< 0.05) compared with
control children. The multiple logistic regression analysis
with correction for age and sex revealed that the fre-
quency of the ecNOS4a allele carriers was significantly
higher in dialyzed and conservative treatment patients
than in healthy children. There was no significant differ-
ence between MHD and conservative treatment groups
as regard to aa genotype (P> 0.05).
Comparison of clinical and biochemical characteristics of
carriers of the ecNOS 4a allele (aaþ ab genotypes) and
noncarriers (bb genotype) is shown in Table 3. Interest-
ingly, 85.95% of the ecNOS 4a allele ESRDpatients were
found hypertensive in comparison to the 60.67% patients
of noncarriers (bb genotype) (P¼ 0.04) Also, 35.90% of
the ecNOS 4a allele ESRD patients were found to have
cardiovascular disease in comparison to the 5.13%
patients of noncarriers (bb genotype) (P¼ 0.01). There
were significant differences between the two subgroups
as regard to triglycerides and HDL cholesterolCopyright © Lippincott Williams & Wilkins. Unaut
Table 1 Clinical and biochemical data of the studied groups
CT (n¼32)
Age 9.147.59
Sex (male/female) 15 (46.88%)/17 (53.12%)
SBP (mmHg) 98.666.66
DBP (mmHg) 64.666.67
Creatinine (mg/dl) 3.933.75aM
Predialysis urea (mg/dl) 51.1210.45aM
Dialysis (years)
Kt/V
Total cholesterol (mg/dl) 164.4450.10
Triglycerides (mg/dl) 160.7857.33aMM
HDL cholesterol (mg/dl) 21.351.17aM
Serum nitric oxide level (mmol/l) 91.4828.80aM
Data were evaluated by ANOVA test. Values are presented as meanSD or percenta
adequacy of hemodialysis; MHD, maintenance hemodialysis. aMP<0.05 or aMMP<0.0
vs. CT and MHD.(190.00 57.15 vs. 116.25 48.49mg/dl, P¼ 0.02; and
21.22 7.05 vs. 32.00 15.96mg/dl, P¼ 0.03, respec-
tively). Serum nitric oxide level was found to be lower
in carriers of the ecNOS 4a allele than in noncarriers
(100.29 27.32 vs. 152.73 60.39mmol/l, P¼ 0.04).
To examine the survival bias in evaluating the effect of
the ecNOS4 polymorphism on renal disease, we analyzed
allele and genotype frequencies in MHD patients shorter
than 3 years on dialysis and those dialyzed 3 years or
longer (data not shown). There were no statistically
significant differences between these two groups
(P¼NS), suggesting little or no influence of survival bias
on the outcome of the study.
We performed a multiple linear regression analysis with
backward stepwise selection using all the clinical risk
factors for hypertension and the mutant allele of the
eNOS 4a gene. This analysis revealed that the most
predictive independent risk factors for hypertension were
the mutant allele (b¼ 0.50, P¼ 0.03), nitric oxide level
(b¼ -0.47, P¼ 0.03) and triglyceride (b¼ 0.60, P¼ 0.02)
(Table 4).
A multiple linear regression analysis using a model iden-
tical to the one used to test hypertension was used to test
vascular disease for the relationship with the mutant
allele of the eNOS 4a gene. This analysis suggested that
a allele has a dominant effect on the risk of vascularhorized reproduction of this article is prohibited.
MHD (n¼46) Controls (n¼30)
10.623.49 8.74.51
25 (54.35%)/21 (45.65%) 20 (66.67%)/10 (33.33%)
127.1318.37bM 94.559.80
85.1513.76bM 60.5910.11
6.321.55bM 0.770.34
71.5620.61bM 7.802.64
2.751.59
1.690.42
193.0451.37bM 160.3118.74
147.0066.98bMM 65.3118.35
27.349.88 bM 39.557.94
143.9335.99bMMc 51.8412.39
ge as applicable. CT, conservative treatment; HDL, high-density lipoprotein; Kt/V,
1 vs. controls and CT. bMP<0.05 or bMMP<0.01 vs. control and MHD. cP<0.01
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Table 5 Risk factors affecting cardiovascular disease in chronic
kidney disease patients based on multiple linear regression
analysis
b P value
Age 0.07 NS
Hypertension% 0. 60 0.02M
SBP 2.19 0.03M
DBP 2.60 0.02M
Serum NO level (mmol/l) 0.41 0.03M
Mutant allele (a allele) 0.99 0.04M
NO, nitric oxide. MP<0.05 was considered significant.
Table 3 Clinical characteristics of chronic kidney disease patients
with different ecNOS intron 4 genotypes
aaþ ab (n¼39) bb (n¼39) P value
Age 11.664.77 9.333.25 NS
SBP (mmHg) 120.2522.47 114.0015.95 NS
DBP (mmHg) 79.3713.40 77.4713.80 NS
Hypertensive% 85.95% 60.67% 0.04M
Cardiovascular disease% 14 (35.90%) 2 (5.13%) 0.01M
Total cholesterol (mg/dl) 183.0038.96 180.0068.67 NS
Triglycerides (mg/dl) 190.0057.15 116.2548.49 0.02M
HDL cholesterol (mg/dl) 21.227.05 32.0015.96 0.03M
Creatinine (mg/dl) 5.992.06 5.442.15 NS
Predialysis urea (mg/dl) 69.8827.84 67.0023.01 NS
Serum NO level (mmol/l) 100.2927.32 152.7360.39 0.04M
Significance was estimated using independent t-test. Data are meanSD. HDL,
high-density lipoprotein; NO, nitric oxide; NS, nonsignificant. MP is significant if it is
less than 0.05.complications in these children (ß¼ 0.99, P¼ 0.04)
(Table 5).
Discussion
Chronic renal failure is a multifactorial disease with
different prevalence and clinical phenotype in different
populations. In this study, the frequency of a allele in the
ecNOS intron 4 was significantly higher in both dialyzed
and conservative treatment patients compared with
healthy controls indicating that the ecNOS 4a allele is
a risk factor for ESRD in children with CKD. Such an
association was observed earlier by others. Asakimori et al.
[9] found a significantly higher frequency of the ecNOS
4a allele in hemodialysis patients, both nondiabetic and
diabetic, and therefore suggested that the polymorphism
in intron 4 of the ecNOS gene may have influence on the
progression of renal disease. Wang et al. [7] in their study
of 302 patients with ESRD and 248 healthy controls
found a significantly higher frequency of the ecNOS
4a allele in patients with ESRD caused by nondiabetic
primary renal diseases. Freedman et al. [14] evaluated the
role of four NOS gene polymorphisms in ESRD patients
and found that a allele of the ecNOS 4 polymorphism
in the NOS gene was associated with all-cause ESRD
in probands and their siblings compared with healthy
subjects.
In our study, there was a significant elevation of serum
nitric oxide levels in patients with CKD either on MHD
or on conservative treatment compared to the controls
and the level was significantly higher in the MHD group
than conservative treatment group. Nitric oxide, anopyright © Lippincott Williams & Wilkins. Unauth
Table 4 Risk factors affecting hypertension in chronic kidney
disease patients based on multiple linear regression analysis
b P value
Age 0.06 NS
Triglycerides (mg/dl) 0.60 0.02M
Serum NO level (mmol/l) 0.47 0.03M
Mutant allele (a allele) 0.50 0.03M
NO, nitric oxide. MP<0.05 was considered significant.extensively studied endothelium relaxing factor, is
reported to be a very potent regulator of intrarenal
hemodynamics [15,16]. It plays a major role in the regu-
lation of cardiovascular homeostasis both in health and
disease. Many studies have published the relation
between nitric oxide and renal failure. An impaired
response to nitric oxide may contribute to the initiation
or maintenance of the increased intraglomerular high
pressure state. The impaired response to nitric oxide
appeared more in MHD patients as they are more
exposed to increased oxidative stress and this may
explain the higher level in this group [17].
In the present study, serum nitric oxide level was found
to be lower in carriers of the ecNOS 4a allele than in
noncarriers. Gururajan et al. [18] reported a strong associ-
ation between a allele of the ecNOS gene and the plasma
NOx (nitrite and nitrate) levels. The mean plasma level
of NOx of the patients who were homozygous for a allele
was nearly 20% lower than in the patients with the b
allele. Although it is disputable whether the nitric oxide
metabolites in the blood are derived entirely from ecNOS
in the endothelial cells of the blood vessels, it is a fact that
plasma nitric oxide levels are different depending on
ecNOS gene polymorphism. They concluded therefore
that the ecNOS gene locus might be responsible for
variations in the genetic control of plasma NOx. The
molecular mechanism by which ecNOS gene polymorph-
ism acts to affect the occurrence of ESRD is not known,
and it is also unclear whether this polymorphism is a
causative variant or a marker of another functional var-
iant. However, the fact that the distribution of a allele in
the ecNOS intron 4 showing a significantly higher inci-
dence in children with CKD and plasma nitric oxide
metabolite levels are reported to be different in depend-
ing on ecNOS gene polymorphism, suggests that the
ecNOS intron 4 is a useful marker for studying the
relationship between nitric oxide and the progression
of renal disease.
The patients of the MHD group have been dialyzed for
relatively long periods. Therefore, we examined the
survival bias. The frequencies of ecNOS intron 4 gene
polymorphism in the long dialysis period group did not
differ from those in the short period group. It appears
therefore, that neither death nor survival is factor inorized reproduction of this article is prohibited.
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progression.
In this study, 85.95% of the ecNOS 4a allele ESRD
patients were found hypertensive in comparison to the
60.67% patients of noncarriers (bb genotype) and on
correlating the DBP to a allele and other individual vari-
ables by multiple linear regression analysis, a allele, nitric
oxide level and triglyceride concentration were variables
that were independently associated with DBP (P< 0.05).
A study using mice with disrupted eNOS gene revealed
that eNOS function is required for vascular and hemody-
namic responses to acetylcholine and that the disruption of
the eNOS gene leads to hypertension [19]. Clinical and
experimental studies suggest that an alteration in nitric
oxide metabolism may be a contributing factor in the
pathogenesis of hypertension. Thus, abnormalities in
the activity of the enzyme eNOS that synthesizes nitric
oxide in endothelial cells may lead to nitric oxide abnorm-
ality with severe consequences [20]. Inhibition of eNOS
elevates blood pressure in healthy humans [21]. Further-
more, nitric oxide production is diminished in patients
with essential hypertension, under basal conditions [22].
Our study revealed that 35.90% of the ecNOS 4a allele
ESRD patients were found to have cardiovascular disease
in comparison to the 5.13% patients of noncarriers (bb
genotype) and that the allele has a dominant effect on the
risk of vascular complications in children with CKD by
multiple linear regression analysis. Apart from controlling
the coronary blood flow, there is now an emerging con-
sensus that nitric oxide generally acts to fine-tune and
optimize cardiac pump function [23]. Excessive nitric
oxide depresses systolic function by decreasing myo-
cardial contractility and shortening the ejection period
[23]. Elevated circulating levels of oxidative products of
(NOx) and myocardial nitric oxide synthetase expression
have been seen in patients with heart failure due to
contractile dysfunction [24,25]. We had a previous study
on the relation between plasma nitric oxide level and left-
ventricular (LV) diastolic function and its cause in heart
failure patients in the pediatric age group. We found that
the plasma NOx levels are elevated in patients with
isolated diastolic heart failure; in addition, in patients
with LV systolic failure, the severity of LV diastolic
dysfunction determines the amount of nitric oxide pro-
duction [26]. Many studies reported a correlation of this
polymorphism with vascular diseases [27–29].
In summary, a allele of the ecNOS intron 4 gene poly-
morphism showed a significantly higher frequency in
children with CKD, both on MHD and conservative
treatment. These results suggest that the ecNOS gene
polymorphism can serve as a useful genetic marker for
evaluation of susceptibility to chronic renal failure. How-
ever, the interactions between this genetic predisposition
and environmental factors as well haplotype analysis need
more studies.Copyright © Lippincott Williams & Wilkins. UnautAcknowledgements
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